TL-895 + navtemadlin

TL-895 + navtemadlin is a combination therapy composed of two investigational oral small molecules being actively studied for hematologic malignancies such as myelofibrosis and acute myeloid leukemia. **TL-895** is a highly selective, covalent, irreversible inhibitor of Bruton's tyrosine kinase (BTK) and bone marrow tyrosine kinase X-linked (BMX), designed to disrupt signaling pathways that promote survival, proliferation, and trafficking of malignant stem and progenitor cells. **Navtemadlin** (KRT-232/AMG 232) is a potent, selective MDM2 inhibitor, restoring wild-type p53 function and triggering apoptosis in cancer cells. In combination, these drugs exhibit synergistic effects: TL-895 treatment sensitizes MPN-blast phase stem cells to navtemadlin-induced apoptosis by activating p53 and antagonizing pro-survival NF-κB transcription, while navtemadlin increases apoptotic signaling via p53 pathway activation. Preclinical and early clinical studies demonstrate that the combination leads to significant depletion of leukemic CD34+ stem/progenitor cells, reduced disease burden, and enhanced cancer cell clearance, notably in TP53 wild-type settings[1][3][5][7]. Both drugs are being developed for oral administration.

Brand names

navtemadlinTL-895TL895TL 895

Other names

KRT-232KRT232KRT 232navtemadlinTL-895TL895TL 895